dasiglucagon (Zegalogue)
Jump to navigation
Jump to search
Indications
- hypoglycemia in patients with diabetes mellitus
Dosage
* 0.6 mL of 1 mg/mL autoinjector or pre-filled syringe for subcutaneous injection
Adverse effects
Drug interactions
- indomethacin: dasiglucagon may lose its ability to raise blood glucose or may produce hypoglycemia
- dasiglucagon may increase anticoagulant effect of warfarin
Mechanism of action
More general terms
References
- ↑ Alicea J FDA Approves Dasiglucagon for Severe Hypoglycemia in Diabetic Patients. HCP Live. March 23, 2021 https://www.hcplive.com/view/fda-approves-dasiglucagon-severe-hypoglycemia-diabetic-patients
- ↑ Li S, Hu Y, Tan X Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes. Expert Opin Pharmacother 2020 Aug;21(11):1311-1318 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32267182
- ↑ ZEGALOGUE HIGHLIGHTS OF PRESCRIBING INFORMATION https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf